United Therapeutics (UTHR) Stock Price, News & Analysis

Company Overview

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs. In addition to its PAH portfolio, United Therapeutics markets dinutuximab (Unituxin) for high-risk neuroblastoma and continues to expand its therapeutic reach through ongoing clinical programs.

Founded in 1996 and headquartered in Silver Spring, Maryland, United Therapeutics has combined its core expertise in vascular biology with innovative manufacturing technologies. Beyond pharmaceuticals, the company’s Lung Biotechnology PBC subsidiary explores regenerative medicine approaches, including decellularized and recellularized organ scaffolds and xenotransplantation methods aimed at addressing organ shortages. Its research pipeline encompasses next-generation agents for PAH, oncology, and transplant applications, reflecting a broad commitment to extending and improving life for patients with complex diseases.

United Therapeutics operates globally, with commercial and clinical efforts spanning North America, Europe, and Asia. Its international infrastructure supports regulatory submissions and patient access programs in key markets such as the European Union and Japan. Under the leadership of founder and Chief Executive Officer Martine Rothblatt, the company emphasizes a multidisciplinary culture that integrates basic science, engineering and patient advocacy. This approach drives its mission to pioneer transformational therapies and sustainable organ manufacturing technologies for conditions with high unmet medical need.

Key Stats

• Today's Range: $508.15 to $514.30
• 50-Day Range: $499.73 to $563.70
• 52-Week Range: $302.19 to $609.35
• Volume: 323,886 shs
• Average Volume: 536,138 shs
• Market Capitalization: $22.00 billion
• P/E Ratio: 18.35
• Dividend Yield: N/A
• Price Target: $646.00
• Consensus Rating: Moderate Buy

United Therapeutics Stock Analysis - MarketRank™

United Therapeutics scored higher than 84% of companies evaluated by MarketBeat, and ranked 76th out of 917 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

United Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on no strong buy ratings, 11 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

United Therapeutics has a consensus price target of $646.00, representing about 26.0% upside from its current price of $512.88.

Amount of Analyst Coverage

United Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 12.69%

Earnings Growth

Earnings for United Therapeutics are expected to grow by 12.69% in the coming year, from $26.33 to $29.67 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of United Therapeutics is 18.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.61.

Price to Earnings Ratio vs. Sector

The P/E ratio of United Therapeutics is 18.35, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.38.

Price to Earnings Growth Ratio

United Therapeutics has a PEG Ratio of 1.74. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

United Therapeutics has a P/B Ratio of 3.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.92% of the float of United Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

United Therapeutics has a short interest ratio ("days to cover") of 5.52.

Change versus previous month

Short interest in United Therapeutics has recently increased by 11.20%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

United Therapeutics does not currently pay a dividend.

Dividend Growth

United Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.22

News Sentiment

United Therapeutics has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 34 news articles for United Therapeutics this week, compared to 11 articles on an average week.

Search Interest

Only 3 people have searched for UTHR on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

4 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $244,251,035.00 in company stock.

Percentage Held by Insiders

8.60% of the stock of United Therapeutics is held by insiders.

Percentage Held by Institutions

94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 8/24/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:UTHR
• CIK: 1082554
• Web: www.unither.com
• Phone: (301) 608-9292
• Fax: 301-608-9291
• Employees: 1,400
• Year Founded: 1996

Price Target and Rating

• Average Price Target for United Therapeutics: $646.00
• High Price Target: $735.00
• Low Price Target: $515.00
• Potential Upside/Downside: +26.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.85
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): $27.95
• Trailing P/E Ratio: 18.35
• Forward P/E Ratio: 19.48
• P/E Growth: 1.74
• Net Income: $1.33 billion
• Net Margins: 41.56%
• Pretax Margin: 49.87%
• Return on Equity: 20.18%
• Return on Assets: 17.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.73
• Quick Ratio: 5.41

Sales & Book Value

• Annual Sales: $3.18 billion
• Price / Sales: 6.91
• Cash Flow: $32.96 per share
• Price / Cash Flow: 15.56
• Book Value: $164.81 per share
• Price / Book: 3.11

Miscellaneous

• Outstanding Shares: 42,890,000
• Free Float: 39,202,000
• Market Cap: $22.00 billion
• Optionable: Optionable
• Beta: 0.59